Diabetes
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Published in Drug Law Weekly, November 20th, 2007
CV Therapeutics, Inc. (NASDAQ:CVTX) announced that data from a prospectively identified analysis of 2,220 diabetic patients from the MERLIN TIMI-36 study showed that Ranexa(R) (ranolazine extended-release tablets) significantly reduced hemoglobin A1c (HbA1c), increased the number of patients achieving the clinical HbA1c treatment target of 7.0 percent or less and reduced the incidence of newly increased HbA1c in patients without diabetes at baseline.
The findings were presented today at the American Heart Association Scientific Sessions in Orlando, Florida by Dr. David Morrow of the TIMI Study Group.
In patients with diabetes treated with Ranexa in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2007-11-20)
More Articles from Drug Law Weekly
- Allergies
AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies - Artificial Grafts
Phoenix Hospital and Two Doctors' Groups to Pay U.S. $6.7 Million to Settle False Claims Act Allegations - ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. Announces Pricing of its Initial Public Offering - Biotechnology
Influential Health Care Companies to Present at 19th Annual Piper Jaffray Health Care Conference - Biotechnology Business
Biovail Enters into Development Agreement - Breast Implants
Heart Bypass Surgery Drug Causing Kidney/Renal Failure Suspended; Anapol Schwartz Attorney -- Representing Victims -- Says Situation Could Be Next Baycol - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
